PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Обратная связь
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0
  • ClinicalTrialUtilities: обзор

Галерея

IMG-20170806-WA0039
20180815 171426
20170804 134902
20170804 174051
IMG-20170806-WA0006
DJI 0002
  • Copiktra (duvelisib): Drug Safety Communication - FDA Warns about Possible Increased Risk of Death and Serious Side Effects
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-06-30 By FDA
  • Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
  • Vaccines Research
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
  • Generic Drugs Program Activities Report - Monthly Performance
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-06-30 By FDA
  • Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Thyroid Neoplasms, Date of authorisation: 16/02/2012, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
  • Human medicines European public assessment report (EPAR): Xelevia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 21/03/2007, Revision: 34, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
  • FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
    Source: FDA - What's New: Drugs RSS Feed Published on 2022-06-30 By FDA
  • Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
  • Update: COVID-19 Vaccine Booster Composition
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
  • COVID-19 Vaccines
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
  • Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides residues in food of animal origin
    Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2022-06-30
  • Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 20/03/2007, Revision: 30, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
  • Human medicines European public assessment report (EPAR): Abiraterone Mylan, abiraterone acetate, Prostatic Neoplasms, Date of authorisation: 20/08/2021, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
  • Human medicines European public assessment report (EPAR): Rapiscan, regadenoson, Myocardial Perfusion Imaging, Date of authorisation: 06/09/2010, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
  • Human medicines European public assessment report (EPAR): Velmetia, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 16/07/2008, Revision: 32, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
Предыдущие записи
Тема: Scaffold от Danny Cooper.